Weight Loss Wars Intensify as Novo sues to keep copycats off shelves

Watch on YouTube ↗  |  February 10, 2026 at 17:32  |  9:49  |  Bloomberg Markets
Speakers
Madison Muller — Bloomberg Reporter

Summary

Madison Muller discusses Novo Nordisk's patent-infringement lawsuit against Hims & Hers over compounded semaglutide, calling it a new escalation in the weight-loss drug wars. She explains why Novo is under more pressure than Eli Lilly due to patent cliffs, supply issues, and a weaker pipeline. The conversation also covers Lilly's Orna Therapeutics acquisition and diversification beyond obesity, plus pricing dynamics, cash-pay patients, and demand resilience for GLP-1 drugs.

  • Novo sues Hims for patent infringement over compounded semaglutide.
  • Hims continued compounding after the shortage ended, creating legal risk.
  • Novo faces earlier patent expirations and a less exciting pipeline than Lilly.
  • Lilly is better positioned with longer patent life, supply control, and aggressive compounding strategy.
  • Lilly is diversifying beyond obesity via Orna and other therapeutic areas.
  • Obesity drug market has significant cash-pay component and faster price declines.
  • Patients may resist switching from branded drugs to cheaper generics.
  • Super Bowl healthy-eating messaging unlikely to eliminate GLP-1 demand because obesity is a disease.
Ideas
Madison Muller Bloomberg Reporter 0:18
Hims faces Novo patent-infringement risk.
Hims & Hers kept compounding GLP-1 drugs after the shortage ended despite limited FDA enforcement, a risky legal bet. Novo Nordisk is now suing Hims for patent infringement on semaglutide, the first such patent suit over compounded semaglutide, and Hims has scrapped a copycat Wegovy pill. This increases legal and business-model risk for Hims.
HIMS HIGH
Madison Muller Bloomberg Reporter 2:23
Novo faces patent cliff and weak pipeline.
Novo Nordisk is under more pressure than Eli Lilly because its GLP-1 drugs are older and lose patent protection outside the US sooner, with semaglutide patents falling globally within the next year; it struggled longer with supply shortages and was less aggressive against compounders; and its next-generation pipeline is less exciting, leaving it less well set up for the future.
NVO HIGH
Madison Muller Bloomberg Reporter 2:29
Lilly better positioned than Novo.
Eli Lilly is purposefully diversifying beyond obesity, learning from Prozac's patent cliff. Its acquisition of Orna Therapeutics and expansion into immunology, cancer, and genetic medicines, with gene therapies now a third of its portfolio, broaden its pipeline and reduce long-term reliance on Zepbound, while it still tests obesity drugs across 5% to 30% weight loss to have something for everyone.
LLY HIGH
Madison Muller Bloomberg Reporter 7:57
Obesity drug demand remains resilient.
Lifestyle or processed-food messaging may not materially reduce GLP-1 demand because obesity is a disease and for many people diet and exercise do not solve it. Drugmakers themselves say healthy eating is important but present medication as part of the solution, supporting resilient demand for obesity drugs.
OZEM MED
Up Next
4:02
Fewer Regulations Expected to Help Power Ford Earnings
Bloomberg Markets · Feb 10
1:52:05
Commerce Sec. Lutnick testifies before lawmakers on broadband deployment funding — 2/10/2026
CNBC · Feb 10
3:09
Ferrari Sets New Targets for 2026, Reassuring Investors
Bloomberg Markets · Feb 10
1:09:00
Position Sizing When Markets Break feat. Rob Carver | Systematic Investor | Ep.386
Top Traders Unplugged · Feb 10
2:24:09
Bloomberg Surveillance 2/10/2026
Bloomberg Markets · Feb 10

This Bloomberg Markets video, published February 10, 2026, features Madison Muller discussing HIMS, NVO, LLY, OZEM. 4 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Madison Muller  · Tickers: HIMS, NVO, LLY, OZEM